AtriCure, Inc. 8-K

What Happened

• AtriCure, Inc. filed an 8‑K on May 19, 2026 reporting results of its May 18, 2026 Annual Meeting. Stockholders approved an amendment to the AtriCure 2023 Stock Incentive Plan to increase the number of shares authorized for issuance from 4,500,000 to 6,000,000 (an increase of 1,500,000 shares).
• At the same meeting, stockholders elected nine directors to one‑year terms, ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026, approved an amendment to the 2018 Employee Stock Purchase Plan (ESPP) to add 750,000 shares, and approved the advisory (non‑binding) say‑on‑pay vote.

Key Details

• 2023 Stock Incentive Plan: increased from 4,500,000 to 6,000,000 shares (approved May 18, 2026). The amended plan allows options, SARs, restricted shares/units and other awards; it prohibits repricing without shareholder approval and contains no automatic “evergreen” share increases.
• ESPP: approved increase of 750,000 shares (amended and restated as of May 18, 2026).
• Auditor ratification: Deloitte & Touche LLP ratified for fiscal year ending Dec 31, 2026 (vote: For 43,617,566; Against 2,327,505; Abstain 57,020).
• Say‑on‑pay: advisory vote on executive compensation approved (For 40,373,427; Against 1,745,379; Abstain 62,342).

Why It Matters

• The increase in the 2023 Stock Incentive Plan and the ESPP expands the company’s capacity to grant equity awards for recruiting, retention and incentive pay—useful for management and employee alignment but potentially dilutive to existing shareholders as more shares may be issued.
• Ratification of the auditor and election of the board are routine governance items that maintain continuity in oversight and financial reporting. The passed advisory say‑on‑pay indicates stockholder support for the company’s executive compensation approach (non‑binding).